No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Obizur is a hematological drug used to treat bleeding episodes in adults with acquired hemophilia A. It is a recombinant human antithrombin (rhAT) that works by inhibiting the activity of clotting factors in the blood. Obizur is administered as an intravenous infusion and is indicated for the treatment of bleeding episodes in adults with acquired hemophilia A. Obizur is the only approved rhAT product for this indication.
Obizur is manufactured by Shire, a global biopharmaceutical company. Other companies in the Obizur market include CSL Behring, Grifols, and Octapharma. These companies are involved in the development and commercialization of hematological drugs, including Obizur. Show Less Read more
